Clinical Trial Update: Dynamic PET/CT Evaluated the Response of Neoadjuvant Anti-PD1 Combination With Chemotherapy for Ⅱa-Ⅲb NSCLC [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating dynamic PET/CT to assess response to neoadjuvant anti-PD1 plus chemotherapy in stage II to III non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Anti-PD1
• Chemotherapy (chemotherapy)

Snippet

Sponsor: Fifth Affiliated Hospital, Sun Yat-Sen University | Conditions: Non-small Cell Lung Cancer Stage II, Non-small Cell Lung Cancer Stage III | Phase 2 | Status: UNKNOWN